MEKanistic Therapeutics Inc.’s First-in-Class Dual EGFR and PI3K Investigational Therapy, MTX-531, Demonstrates Significant Tolerability and Durable Tumor Regressions in Preclinical Cancer Models

New MTX-531 Research in Nature Cancer Highlights Promising Dual Inhibitor Strategy for Overcoming Cancer Resistance MINNEAPOLIS, July 11, 2024 /PRNewswire/ — MEKanistic Therapeutics Inc., a biotechnology company pioneering the development of next-generation kinase inhibitors for cancer…